Prophylactic cholecystectomy in midgut carcinoid patients

World Journal of Surgery

Volumn 34, Issue 6, 2010, Pages 1361-1367

  Norlén, Olov ^a   Hessman, Ola ^a   Stålberg, Peter ^a   Åkerström, Göran ^a   Hellman, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARCINOID SYNDROME; CHOLECYSTECTOMY; FEMALE; GALLSTONE; GASTROINTESTINAL TUMOR; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHOLECYSTECTOMY; FEMALE; GALLSTONES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955555311     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-010-0428-1     Document Type: Article

References (41)

1. Arnold R, Müller H, Schade-Brittinger C et al (2009) Placebocontrolled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27:15s (Suppl; abstr 4508)
2. Buscail LE, Puel-Bousquet C, Harris AG et al (1991) Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment. Gastroenterol Clin Biol 15:800-804
3. Dowling RH, Hussaini SH, Murphy GM et al (1992) Gallstones during octreotide therapy. Metabolism 41:22-33
4. Moschetta A, Stolk MF, Rehfeld JF et al (2001) Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 15:181-185
5. Stolk MF, van Erpecum KJ, Koppeschaar HP et al (1993) Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly. Gut 34:808-813
6. vanBerge-Henegouwen GP, Venneman NG, van Erpecum KJ et al (2005) Drugs affecting biliary lipid secretion and gallbladder motility: their potential role in gallstone treatment and prevention. Curr Drug Targets Immune Endocr Metabol Disord 5:185-191
7. Zhou JH, Liu CY, Zhang RH et al (1998) Effects of octreotide on gallbladder pressure and myoelectric activity of Oddi sphincter in rabbits. World J Gastroenterol 4:238-241
8. Shaffer EA (2006) Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 20:981-996
9. Shaffer EA (2005) Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 7:132-140
10. Lapidus A, Bangstad M, Astrom M et al (1999) The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol 94:1261-1266
11. Katsika D, Tuvblad C, Einarsson C et al (2007) Body mass index, alcohol, tobacco and symptomatic gallstone disease: a Swedish twin study. J Int Med 262:581-587
12. Torgerson JS, Lindroos AK, Naslund I et al (2003) Gallstones, gallbladder disease, and pancreatitis: cross-sectional and 2-year data from the Swedish Obese Subjects (SOS) and SOS reference studies. Am J Gastroenterol 98:1032-1041
13. Attanasio R, Mainolfi A, Grimaldi F et al (2008) Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. J Endocrinol Invest 31:704-710
14. Montini M, Gianola D, Pagani MD et al (1994) Cholelithiasis and acromegaly: therapeutic strategies. Clin Endocrinol (Oxf) 40:401-406
15. Muhrbeck O, Ahlberg J (1995) Prevalence of gallstone disease in a Swedish population. Scand J Gastroenterol 30:1125-1128
16. Borch K, Jonsson KA, Zdolsek JM et al (1998) Prevalence of gallstone disease in a Swedish population sample. Relations to occupation, childbirth, health status, life style, medications, and blood lipids. Scand J Gastroenterol 33:1219-1225
17. Janzon L, Aspelin P, Eriksson S et al (1985) Ultrasonographic screening for gallstone disease in middle-aged women. Detection rate, symptoms, and biochemical features. Scand J Gastroenterol 20:706-710
18. Mellstrom D, Asztely M, Svanvik J (1988) Gallstones and previous cholecystectomy in 77- to 78-year-old women in an urban population in Sweden. Scand J Gastroenterol 23:1241-1244
19. Trendle MC, Moertel CG, Kvols LK (1997) Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 79:830-834
20. Urbach DR, Stukel TA (2005) Rate of elective cholecystectomy and the incidence of severe gallstone disease. CMAJ 172:1015-1019
21. Muhrbeck O (1995) Symptoms of gallstone disease in a Swedish population. Eur J Gastroenterol Hepatol 7:1209-1214
22. Lindstrom CG (1977) Frequency of gallstone disease in a welldefined Swedish population. A prospective necropsy study in Malmo. Scand J Gastroenterol 12:341-346
23. Paisley AN, Roberts ME, Trainer PJ (2007) Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol (Oxf) 66:723-726
24. Yamamoto T, Kubo S, Hirohashi K et al (2003) Secondary hemocholecyst after radiofrequency ablation therapy for hepatocellular carcinoma. J Gastroenterol 38:399-403
25. Chen TM, Huang PT, Lin LF et al (2008) Major complications of ultrasound-guided percutaneous radiofrequency ablations for liver malignancies: single-center experience. J Gastroenterol Hepatol 23:e445-e450
26. Chopra S, Dodd GD III, Chanin MP et al (2003) Radiofrequency ablation of hepatic tumors adjacent to the gallbladder: feasibility and safety. AJR Am J Roentgenol 180:697-701
27. Gross-Fengels W, Friedmann G, Kuhn M et al (1991) Techniques, results and risks of chemoembolization of malignant liver tumors. Aktuelle Radiol 1:97-104
28. Drougas JG, Anthony LB, Blair TK et al (1998) Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 175:408-412
29. Lammer J, Justich E, Schreyer H et al (1983) Therapeutic embolization with polyvinyl alcohol (Ivalon). Clinical experiences. Rontgenblatter 36:152-157
30. Salman HS, Cynamon J, Jagust M et al (2002) Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2:173-179
31. Tsuji M, Iwata Y, Harada T et al (1987) Hepatic arterial collaterals in Ivalon embolization of the hepatic artery. Rinsho Hoshasen 32:801-805
32. Pitt SC, Knuth J, Keily JM et al (2008) Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12:1951-1960
33. Herzog U, Bertschmann W (1990) Postoperative mortality in surgery of cholelithiasis: a retrospective analysis from the years 1972-1980. Schweiz Rundsch Med Prax 79:287-290
34. McSherry CK (1989) Cholecystectomy: the gold standard. Am J Surg 158:174-178
35. Ludwig K, Kockerling F, Hohenberger W et al (2001) Surgical therapy in cholecysto-/choledocholithiasis. Results of a Germanywide questionnaire sent to 859 clinics with 123, 090 cases of cholecystectomy. Chirurg 72:1171-1178
36. Sakorafas GH, Milingos D, Peros G (2007) Asymptomatic cholelithiasis: is cholecystectomy really needed? A critical reappraisal 15 years after the introduction of laparoscopic cholecystectomy. Dig Dis Sci 52:1313-1325
37. Biagini J (1989) Asymptomatic cholelithiasis. When is a cholecystectomy justified? J Med Liban 38:51-55
38. Schirmer BD, Winters KL, Edlich RF (2005) Cholelithiasis and cholecystitis. J Long Term Eff Med Implants 15:329-338
39. Plaisier PW, van der Hul RL, Terpstra OT et al (1993) Current treatment modalities for symptomatic gallstones. Am J Gastroenterol 88:633-639
40. Keulemans YC, Venneman NG, Gouma DJ et al (2002) New strategies for the treatment of gallstone disease. Scand J Gastroenterol- Suppl 87-90
41. Picci R, Perri SG, Dalla Torre A et al (2005) Therapy of asymptomatic gallstones: indications and limits. Chir Ital 57:35-45